State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Sciences, School of Chemical Engineering, Dalian University of Technology, Dalian.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Neuroreport. 2021 Sep 8;32(13):1140-1146. doi: 10.1097/WNR.0000000000001706.
Ischemic stroke continues to be a major global health problem associated with considerable mortality and morbidity. Thus, it is still targeted by researchers for developing new strategies or drugs to alleviate the lesion of stroke. In the present study, both the permanent occlusion of the middle cerebral artery (MCAO) model and the restoration of cerebral blood flow after middle cerebral artery occlusion (CI/R) model were set up for evaluating the efficiency of salvianolic acid B and ginsenoside Rg1 combination (SalB-Rg1). SalB-Rg1 decreased infarct area through 3,5-triphenyltetrazolium chloride stain and improved neurological behavior through Longa Score or Left-Biased Swings on both MCAO rats and CI/R rats. Neural protection of SalB-Rg1 against ischemia or ischemic reperfusion injury was evidenced by the inhibition of nucleus pyknosis, liquefaction necrosis through H&E stain and Nissl stain. Furthermore, protection of SalB-Rg1 on blood-brain barrier (BBB) was more significant on CI/R rats, accompanying with the downregulation of matrix metalloproteinase-2 and matrix metalloproteinase-9, and recovery of zonula occludens-1 expression. These results provide compelling evidence that SalB-Rg1 holds the potential to be developed as an optimal therapeutic strategy to alleviate the injury of ischemia or ischemic reperfusion.
缺血性脑卒中仍然是一个主要的全球健康问题，与相当高的死亡率和发病率有关。因此，研究人员仍在致力于开发新的策略或药物来减轻中风的损伤。在本研究中，建立了永久性大脑中动脉闭塞（MCAO）模型和大脑中动脉闭塞后血流恢复（CI/R）模型，以评估丹酚酸 B 和人参皂苷 Rg1 联合（SalB-Rg1）的疗效。SalB-Rg1 通过 3,5-三苯基氯化四氮唑染色减少梗死面积，并通过 Longa 评分或左侧偏斜摆动改善 MCAO 大鼠和 CI/R 大鼠的神经行为。SalB-Rg1 对缺血或缺血再灌注损伤的神经保护作用通过苏木精-伊红（H&E）染色和尼氏染色抑制核固缩、液化性坏死得到证实。此外，SalB-Rg1 在 CI/R 大鼠上对血脑屏障（BBB）的保护作用更为显著，伴随基质金属蛋白酶-2 和基质金属蛋白酶-9 的下调，以及紧密连接蛋白-1 表达的恢复。这些结果提供了有力的证据，表明 SalB-Rg1 有潜力成为一种缓解缺血或缺血再灌注损伤的最佳治疗策略。
